• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

列线图预测肝内胆管细胞癌切除术后的长期生存:东西方经验。

A nomogram to predict long-term survival after resection for intrahepatic cholangiocarcinoma: an Eastern and Western experience.

出版信息

JAMA Surg. 2014 May;149(5):432-8. doi: 10.1001/jamasurg.2013.5168.

DOI:10.1001/jamasurg.2013.5168
PMID:24599477
Abstract

IMPORTANCE

Intrahepatic cholangiocarcinoma (ICC) is a primary cancer of the liver that is increasing in incidence, and the prognostic factors associated with outcome after surgery remain poorly defined.

OBJECTIVE

To combine clinicopathologic variables associated with overall survival after resection of ICC into a prediction nomogram.

DESIGN, SETTING, AND PARTICIPANTS: We performed an international multicenter study of 514 patients who underwent resection for ICC at 13 major hepatobiliary centers in the United States, Europe, and Asia from May 1, 1990, through December 31, 2011. Multivariate Cox proportional hazards regression modeling with backward selection using the Akaike information criteria was used to select variables for construction of the nomogram. Discrimination and calibration were performed using Kaplan-Meier curves and calibration plots.

INTERVENTIONS

Surgical resection of ICC at a participating hospital.

MAIN OUTCOMES AND MEASURES

Long-term survival, effect of potential prognostic factors, and performance of proposed nomogram.

RESULTS

Median patient age was 59.2 years, and 53.1% of the patients were male. Most patients (74.7%) had a solitary tumor, and median tumor size was 6.0 cm. Patients were treated with an extended hepatectomy (202 [39.3%]), a hemihepatectomy (180 [35.0%]), or a minor liver resection (<3 segments) (132 [25.7%]). Most patients underwent R0 resection (87.9%), and 35.7% of patients had N1 disease. Using the backward selection of clinically relevant variables, we found that age at diagnosis (hazard ratio [HR], 1.31; P < .001), tumor size (HR, 1.50; P < .001), multiple tumors (HR, 1.58; P < .001), cirrhosis (HR, 1.51; P = .08), lymph node metastasis (HR, 1.78; P = .01), and macrovascular invasion (HR, 2.10; P < .001) were selected as factors predictive of survival. On the basis of these factors, a nomogram was created to predict survival of ICC after resection. Discrimination using Kaplan-Meier curves, calibration curves, and bootstrap cross-validation revealed good predictive abilities (C index, 0.692).

CONCLUSIONS AND RELEVANCE

On the basis of an Eastern and Western experience, a nomogram was developed to predict overall survival after resection for ICC. Validation revealed good discrimination and calibration, suggesting clinical utility to improve individualized predictions of survival for patients undergoing resection of ICC.

摘要

重要性

肝内胆管细胞癌(ICC)是一种原发性肝癌,其发病率正在增加,与手术后结局相关的预后因素仍未得到明确界定。

目的

将与 ICC 切除术后总体生存相关的临床病理变量结合到一个预测列线图中。

设计、地点和参与者:我们对 1990 年 5 月 1 日至 2011 年 12 月 31 日期间在美国、欧洲和亚洲的 13 个主要肝胆中心接受 ICC 切除术的 514 例患者进行了一项国际多中心研究。使用向后选择的 Akaike 信息准则的多变量 Cox 比例风险回归模型用于选择构建列线图的变量。使用 Kaplan-Meier 曲线和校准图进行区分度和校准评估。

干预措施

在参与医院进行 ICC 切除术。

主要结果和测量

长期生存、潜在预后因素的影响以及提出的列线图的性能。

结果

中位患者年龄为 59.2 岁,53.1%的患者为男性。大多数患者(74.7%)有单个肿瘤,肿瘤大小中位数为 6.0cm。患者接受了扩大肝切除术(202 [39.3%])、半肝切除术(180 [35.0%])或小范围肝切除术(<3 个节段)(132 [25.7%])。大多数患者接受了 R0 切除术(87.9%),35.7%的患者存在 N1 疾病。通过对临床相关变量的向后选择,我们发现诊断时的年龄(风险比[HR],1.31;P<0.001)、肿瘤大小(HR,1.50;P<0.001)、多个肿瘤(HR,1.58;P<0.001)、肝硬化(HR,1.51;P=0.08)、淋巴结转移(HR,1.78;P=0.01)和大血管侵犯(HR,2.10;P<0.001)被选为与生存相关的预测因素。基于这些因素,创建了一个列线图来预测 ICC 切除术后的生存。使用 Kaplan-Meier 曲线、校准曲线和自举交叉验证进行区分度评估显示出良好的预测能力(C 指数,0.692)。

结论和相关性

基于东西方的经验,开发了一个列线图来预测 ICC 切除术后的总体生存率。验证结果显示出良好的区分度和校准度,表明该列线图具有临床应用价值,可提高接受 ICC 切除术患者的生存个体化预测能力。

相似文献

1
A nomogram to predict long-term survival after resection for intrahepatic cholangiocarcinoma: an Eastern and Western experience.列线图预测肝内胆管细胞癌切除术后的长期生存:东西方经验。
JAMA Surg. 2014 May;149(5):432-8. doi: 10.1001/jamasurg.2013.5168.
2
Prognostic nomogram for intrahepatic cholangiocarcinoma after partial hepatectomy.肝内胆管癌根治性切除术后的预后列线图。
J Clin Oncol. 2013 Mar 20;31(9):1188-95. doi: 10.1200/JCO.2012.41.5984. Epub 2013 Jan 28.
3
Staging, prognostic factors and adjuvant therapy of intrahepatic cholangiocarcinoma after curative resection.肝内胆管癌根治性切除术后的分期、预后因素及辅助治疗
Liver Int. 2014 Jul;34(6):953-60. doi: 10.1111/liv.12364. Epub 2013 Nov 20.
4
Concomitant Precise Hemihepatectomy to Improve the Efficacy of Surgical Treatment for Hilar Cholangiocarcinoma: Analysis of 38 Cases.同期精准半肝切除术提高肝门部胆管癌外科治疗疗效:38例分析
Hepatogastroenterology. 2014 Jun;61(132):927-32.
5
Defining the Benefit of Adjuvant Therapy Following Resection for Intrahepatic Cholangiocarcinoma.确定肝内胆管癌切除术后辅助治疗的益处。
Ann Surg Oncol. 2015 Jul;22(7):2209-17. doi: 10.1245/s10434-014-4275-4. Epub 2014 Dec 5.
6
Multicentric evaluation of a clinical and prognostic scoring system predictive of survival after resection of intrahepatic cholangiocarcinomas.多中心评估临床和预后评分系统对肝内胆管细胞癌切除术后生存的预测价值。
Liver Int. 2010 Aug;30(7):996-1002. doi: 10.1111/j.1478-3231.2010.02203.x. Epub 2010 Feb 5.
7
Model to predict survival after surgical resection of intrahepatic cholangiocarcinoma: the Mayo Clinic experience.预测肝内胆管癌手术切除后生存率的模型:梅奥诊所的经验
HPB (Oxford). 2015 Mar;17(3):244-50. doi: 10.1111/hpb.12333. Epub 2014 Nov 19.
8
Adjuvant Transarterial Chemoembolization Following Liver Resection for Intrahepatic Cholangiocarcinoma Based on Survival Risk Stratification.基于生存风险分层的肝内胆管癌肝切除术后辅助经动脉化疗栓塞术
Oncologist. 2015 Jun;20(6):640-7. doi: 10.1634/theoncologist.2014-0470. Epub 2015 May 8.
9
Survival analysis of intrahepatic cholangiocarcinoma after resection.肝内胆管癌切除术后的生存分析。
Ann Surg Oncol. 2010 Jul;17(7):1823-30. doi: 10.1245/s10434-010-0938-y. Epub 2010 Feb 18.
10
Long-term outcome and prognostic factors of intrahepatic cholangiocarcinoma.肝内胆管癌的长期预后及预后因素。
Chin Med J (Engl). 2009 Oct 5;122(19):2286-91.

引用本文的文献

1
Real-World Single-Center Experience with Neoadjuvant Gemcitabine, Cisplatin, and Durvalumab in Borderline Resectable Cholangiocarcinoma.吉西他滨、顺铂和度伐利尤单抗新辅助治疗可切除边缘胆管癌的单中心真实世界经验
Ann Surg Oncol. 2025 Aug 13. doi: 10.1245/s10434-025-18046-6.
2
Preoperative Prediction of Microvascular Invasion in Intrahepatic Cholangiocarcinoma and Its Prognostic Implications: A Multicenter Study.肝内胆管癌微血管侵犯的术前预测及其预后意义:一项多中心研究
Liver Cancer. 2025 Jun 24. doi: 10.1159/000547071.
3
Preoperative scoring system for predicting microvascular invasion in intrahepatic cholangiocarcinoma using gadoxetate-enhanced MRI.
使用钆塞酸二钠增强MRI预测肝内胆管癌微血管侵犯的术前评分系统
Eur Radiol. 2025 Jun 6. doi: 10.1007/s00330-025-11722-x.
4
Comparison of MRI and prognostic features of intrahepatic cholangiocarcinoma between patients with and without hepatitis B virus infection.乙型肝炎病毒感染患者与未感染患者肝内胆管癌的MRI及预后特征比较。
Abdom Radiol (NY). 2025 Jun 3. doi: 10.1007/s00261-025-05034-3.
5
Association of albumin-bilirubin grade with survival outcomes in patients with cholangiocarcinoma.白蛋白-胆红素分级与胆管癌患者生存结局的关联
PLoS One. 2025 May 7;20(5):e0321758. doi: 10.1371/journal.pone.0321758. eCollection 2025.
6
Survival Outcomes of Preoperative Serum Biomarkers in Patients With Surgically Treated Intrahepatic Cholangiocarcinoma.手术治疗的肝内胆管癌患者术前血清生物标志物的生存结果
Clin Transl Gastroenterol. 2025 Apr 18;16(6):e00845. doi: 10.14309/ctg.0000000000000845. eCollection 2025 Jun 1.
7
Prognostic value of CRP-albumin-lymphocyte index in patients with intrahepatic cholangiocarcinoma after radical resection.C反应蛋白-白蛋白-淋巴细胞指数对肝内胆管癌根治性切除术后患者的预后价值
Front Med (Lausanne). 2025 Mar 6;12:1543665. doi: 10.3389/fmed.2025.1543665. eCollection 2025.
8
Should lymphadenectomy be recommended in radical surgery of intrahepatic cholangiocarcinoma patients? A retrospective study.肝内胆管癌患者根治性手术中是否应推荐淋巴结清扫术?一项回顾性研究。
J Cancer Res Clin Oncol. 2025 Mar 12;151(3):107. doi: 10.1007/s00432-025-06148-3.
9
Prognostic Significance of Lymph Node Ratio in Intrahepatic and Extrahepatic Cholangiocarcinomas.淋巴结比率在肝内和肝外胆管癌中的预后意义
Cancers (Basel). 2025 Jan 11;17(2):220. doi: 10.3390/cancers17020220.
10
Introducing and Validating the Multiphasic Evidential Decision-Making Matrix (MedMax) for Clinical Management in Patients with Intrahepatic Cholangiocarcinoma.介绍并验证用于肝内胆管癌患者临床管理的多相循证决策矩阵(MedMax)。
Cancers (Basel). 2024 Dec 27;17(1):52. doi: 10.3390/cancers17010052.